Home›Trial›NCT06179160

🔬NCT06179160Phase 1RECRUITING

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Study Summary

This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

Conditions

Interventions / Drugs

INCB161734 Cetuximab Retifanlimab GEMNabP mFOLFIRINOX FOLFOX FOLFIRI INCA33890

View on ClinicalTrials.gov ↗

Sponsor

Incyte Corporation

Study Details

Enrollment710 participants

Primary Completion—

Lead SponsorIncyte Corporation

Data Retrieved2026-04-11 02:55:29.647472+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.